不同化疗方案对晚期胃癌患者的疗效对比分析  

Comparative analyses of advanced gastric cancer on different chemotherapeutic protocols

作　　者：樊雷[1] 张慧力[1] 

机构地区：[1]中国航天科工集团七三一医院普通外科,北京100074

出　　处：《中华全科医师杂志》2015年第6期450-452,共3页Chinese Journal of General Practitioners

摘　　要：将86例胃癌晚期患者，利用SPSS13．0软件生成随机数字分为观察组和对照组，每组各43例。观察组采用希罗达联合奥沙利铂（XELOX方案）治疗，对照组采用奥沙利铂＋5-氟尿嘧啶＋亚叶酸钙（FOLFOX4方案）治疗，采用实体瘤的疗效评价标准（RECIST）评价近期疗效，并比较两组患者不良反应发生率。观察组与对照组有效率分别为56％、51％，差异无统计学意义（P〉0．05）。观察组骨髓抑制、恶心呕吐发生率低于对照组，差异具有统计学意义（P〈0．05），其余各项不良反应比较差异无统计学意义（P〉0．05）。XELOX与FOLFOX4方案对进展期胃癌近期疗效相近，XELOX方案不良反应轻，患者更易接受，依从性好。Objective A total of 86 cases with advanced gastric cancer were randomly divided into XELOX（ capecitabine plus oxaliplatin ） and FOLFOX4 （ 5-fluorouraeil, leueovorin, and oxaliplatin） groups （n =43 each）. The immediate effieacies were evaluated by the criteria of Response Evaluation Criteria In Solid Tumors （RECIST）. Adverse reactions were compared between two groups. The overall effective rate were 56% and 51% in XELOX and FOLFOX4 groups. And there was no significant inter-group difference （ P 〉 0. 05 ）. The incidences of myelosuppression and nausea, vomiting in XELOX group were lower than those in FOLFOX4 group （P 〈 0.05）. And other adverse reactions had no inter-group statistical difference （P 〉 0.05 ）. Both chemotherapies were comparable in immediate efficacies for advanced gastric cancer. However, XELOX chemotherapy had a lower incidence of adverse reactions and it is more tolerable and compliant for patients.

关 键 词：胃肿瘤 抗肿瘤联合化疗方案 

分 类 号：R735.2[医药卫生—肿瘤]